NO20013675L - 2,3,4,5-tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinase-inhibitorer - Google Patents

2,3,4,5-tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinase-inhibitorer

Info

Publication number
NO20013675L
NO20013675L NO20013675A NO20013675A NO20013675L NO 20013675 L NO20013675 L NO 20013675L NO 20013675 A NO20013675 A NO 20013675A NO 20013675 A NO20013675 A NO 20013675A NO 20013675 L NO20013675 L NO 20013675L
Authority
NO
Norway
Prior art keywords
benzodiazepine
tetrahydro
hydroxamic acid
matrix metalloproteinase
metalloproteinase inhibitors
Prior art date
Application number
NO20013675A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013675D0 (no
Inventor
Jay Donald Albright
Efren Guillermo Delos Santos
Jeremy Ian Levin
James Ming Chen
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO20013675D0 publication Critical patent/NO20013675D0/no
Publication of NO20013675L publication Critical patent/NO20013675L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
NO20013675A 1999-01-27 2001-07-26 2,3,4,5-tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinase-inhibitorer NO20013675L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23908099A 1999-01-27 1999-01-27
PCT/US2000/001991 WO2000044730A1 (en) 1999-01-27 2000-01-27 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
NO20013675D0 NO20013675D0 (no) 2001-07-26
NO20013675L true NO20013675L (no) 2001-09-21

Family

ID=22900512

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013675A NO20013675L (no) 1999-01-27 2001-07-26 2,3,4,5-tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinase-inhibitorer

Country Status (25)

Country Link
EP (1) EP1147095B1 (de)
JP (1) JP2002535392A (de)
KR (1) KR20010101730A (de)
CN (1) CN1197849C (de)
AR (1) AR022423A1 (de)
AT (1) ATE273288T1 (de)
AU (1) AU767039B2 (de)
BG (1) BG105736A (de)
BR (1) BR0007759A (de)
CA (1) CA2356267A1 (de)
CZ (1) CZ20012637A3 (de)
DE (1) DE60012883T2 (de)
EA (1) EA200100809A1 (de)
ES (1) ES2223470T3 (de)
HU (1) HUP0105302A3 (de)
ID (1) ID29046A (de)
IL (1) IL144168A0 (de)
NO (1) NO20013675L (de)
NZ (1) NZ511885A (de)
PL (1) PL349025A1 (de)
PT (1) PT1147095E (de)
SK (1) SK10422001A3 (de)
TR (1) TR200102131T2 (de)
WO (1) WO2000044730A1 (de)
ZA (1) ZA200104321B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US6770647B2 (en) 2001-08-17 2004-08-03 Bristol-Myers Squibb Pharma Company Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
JP2005507937A (ja) 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイション マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7488754B2 (en) 2002-04-05 2009-02-10 Wyeth Method for the treatment of polycystic kidney disease
MXPA05001603A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
JP5069108B2 (ja) 2004-07-21 2012-11-07 メルク セローノ ソシエテ アノニム オクタヒドロピロロ［２，３，ｃ］ピリジン誘導体と、その医薬としての利用法
AU2004322756B2 (en) 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
EP1865001A1 (de) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Spezifische Proteaseinhibitoren und ihre Verwendung in der Krebstherapie
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
FR2950056B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2950057B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US8765814B2 (en) 2010-07-08 2014-07-01 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same
KR101836547B1 (ko) * 2010-09-17 2018-04-19 고쿠리츠다이가쿠호우진 도쿄다이가쿠 혈소판의 기능을 유지하기 위한 조성물
MX2020007997A (es) 2018-02-02 2020-12-03 Alexza Pharmaceuticals Inc Dispositivo electrico de aerosol de condensacion.
EP3860608A1 (de) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr-inhibitoren zur behandlung von keratosen
WO2021055817A1 (en) * 2019-09-19 2021-03-25 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
TR199800849T2 (xx) * 1995-11-13 1998-07-21 Hoechst Aktiengesellschaft Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
EA003294B1 (ru) * 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
HUP0000505A3 (en) * 1996-08-28 2001-12-28 Procter & Gamble Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them
ATE226573T1 (de) * 1996-08-28 2002-11-15 Procter & Gamble Heterozyklische metalloproteaseinhibitoren
CN1228771A (zh) * 1996-08-28 1999-09-15 普罗克特和甘保尔公司 1,3－二杂环金属蛋白酶抑制剂
CN1293663A (zh) * 1998-01-27 2001-05-02 美国氰胺公司 为基质金属蛋白酶抑制剂的2,3,4,5－四氢－1h－[1,4]苯并二氮杂䓬－3－异羟肟酸

Also Published As

Publication number Publication date
KR20010101730A (ko) 2001-11-14
EA200100809A1 (ru) 2002-02-28
NO20013675D0 (no) 2001-07-26
CA2356267A1 (en) 2000-08-03
EP1147095B1 (de) 2004-08-11
AU3216000A (en) 2000-08-18
AU767039B2 (en) 2003-10-30
HUP0105302A3 (en) 2002-09-30
BR0007759A (pt) 2001-11-13
DE60012883T2 (de) 2005-08-25
EP1147095A1 (de) 2001-10-24
BG105736A (en) 2002-05-31
DE60012883D1 (de) 2004-09-16
CN1197849C (zh) 2005-04-20
ES2223470T3 (es) 2005-03-01
JP2002535392A (ja) 2002-10-22
HUP0105302A2 (hu) 2002-07-29
PT1147095E (pt) 2004-12-31
ZA200104321B (en) 2002-08-26
PL349025A1 (en) 2002-07-01
IL144168A0 (en) 2002-05-23
ATE273288T1 (de) 2004-08-15
ID29046A (id) 2001-07-26
NZ511885A (en) 2003-06-30
SK10422001A3 (sk) 2002-09-10
TR200102131T2 (tr) 2001-12-21
CN1337952A (zh) 2002-02-27
AR022423A1 (es) 2002-09-04
CZ20012637A3 (cs) 2002-04-17
WO2000044730A1 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
NO20013675D0 (no) 2,3,4,5-Tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinaseinhibitorer
EE200000720A (et) Uus 3-arüül-2-hüdroksüpropaanhappe derivaat (I)
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20002217L (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1036062T3 (da) Hydroxamsyrederivater som matrix metalloprotease (MMP) inhibitorer
DK1114032T3 (da) 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer
NO20015065L (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
EE200000717A (et) Uus 3-arüül-2-hüdroksüpropaanhappe derivaat III
NO20003828D0 (no) 2,3,4,5-Tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinaseinhibitorer
DK1210326T3 (da) Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer
DE60043730D1 (de) Arylsulfonamid-substituierte hydroxamsäure-derivate
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO991994D0 (no) Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriks-metalloproteaseinhibitorer
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
NO20013853D0 (no) Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer
DK1147080T3 (da) Alkynylholdige hydroxamsyreforbindelser som TACE-inhibitorer
DK1047665T3 (da) Matrix metalloprotease inhibitorer
PL357084A1 (en) Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
DK1487802T3 (da) 2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer
DK1147095T3 (da) 2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepin-3-hydroxamsyrer som matrixmetalloproteinaseinhibitorer
DK1380585T3 (da) Pyrazolopyridinon som mellemprodukt
HK1038013A (en) 2,3,4,5-tetrahydro-1h-[1,4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application